Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN82,8-0,24
Msft-0,72
Nokia5,0645,0921,11
IBM0,02
DCX57,5657,57-0,31
PFE0,58
23.6.2018 2:00:00
Indexy online
AD Index online
select
AD Index online
 

  • 22.6.2018 22:00:00
La Jolla Pharmaceut (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
30,67 0,66 0,20 593 974
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 24.6.2018
Popis společnosti
Obecné informace
Název společnostiLa Jolla Pharmaceutical Company
TickerLJPC
Kmenové akcie:Ordinary Shares
RICLJPC.O
ISINUS5034596040
Prioritní akciePreference Shares Ser. C-1
Prioritní akcieConv. Pref. Shrs Series D-1
Prioritní akcieConv. Pref. Shrs Series C-2
Prioritní akcieConv. Pref. Shrs
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 130
Akcie v oběhu k 23.4.2018 26 154 439
Počet akcionářů k 31.12.2017 4 000
MěnaUSD
Kontaktní informace
Ulice4550 Towne Centre Ct
MěstoSAN DIEGO
PSČ92121-1900
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon18 582 074 264
Fax16194526893

Business Summary: La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH). It has initiated a Phase III trial of LJPC-501 for the treatment of CRH, called the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS) Phase III trial. LJPC-401 is its formulation of synthetic human hepcidin for the potential treatment of conditions characterized by iron overload, such as hereditary hemochromatosis, beta thalassemia, sickle cell disease and myelodysplastic syndrome. LJPC-30S is its next-generation gentamicin derivative program that is focused on therapeutics for the potential treatment of serious bacterial infections, as well as rare genetic disorders, such as cystic fibrosis and Duchenne muscular dystrophy.
Financial Summary: BRIEF: For the three months ended 31 March 2018, La Jolla Pharmaceutical Company revenues increased from $0K to $809K. Net loss increased from $23.2M to $50.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative - other increase from $3M to $19M (expense), Research and development - Balancing val increase of 51% to $23M (expense).
Odvětvová klasifikace
TRBC2012Bio Therapeutic Drugs
RBSS2004Pharmaceuticals - Diversified
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSBiological Product (except Diagnostic) Manufacturing
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
SICBiological Prod's Not Diagnostic
SICBiological Prod's Not Diagnostic
SICCommercial Physical Research



  • Poslední aktualizace: 24.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Chairman of the BoardKevin Tang50
President, Chief Executive Officer, Secretary, DirectorGeorge Tidmarsh5719.1.201219.1.2012
Chief Financial OfficerDennis Mulroy626.4.20156.4.2015
Chief Operating OfficerJennifer Carver63
Chief Scientific OfficerJames Rolke48
Chief Medical OfficerLakhmir Chawla46